Solvay Partners with Mitsubishi Chemical Advanced Materials to Recycle End-of-life Medical Components

New collaboration will help customers reach sustainability goals for high-performance Udel® PSU polymers in demanding applications

Solvay: Medical equipment made using Solvay’s Udel® high-performance polysulfone (PSU) thermoplastic will be recycled at the end of their useful lives in a new sustainability initiative that the company has embarked on with Mitsubishi Chemical Advanced Materials (MCAM).

In line with Solvay’s One Planet sustainability roadmap and Mitsubishi’s KAITEKI vision designed to preserve resources and contribute to safer, cleaner and more sustainable products, both companies are currently investigating the implementation of logistics for recovery, recycling, and reprocessing of Udel® PSU medical components, with the aim of recycled material being suitable for reuse in the original applications.

“The agreement with Mitsubishi Chemical Advanced Materials is the latest demonstration of Solvay’s commitment to help customers achieve ambitious sustainability targets,” says Antonella Di Meo, Product Sustainability Manager at Solvay. “It is part of our long-term commitment to develop sustainable solutions from bio-based or recycled resources. With this project, we want to show, in a practical way, that it is possible to recycle high-value Udel® PSU parts used in the medical field, yielding important savings in CO2 emissions along the production and supply chain.”

The project involves using a combination of the expertise developed by MCAM to wash and mechanically purify the material, together with Solvay’s ability to evaluate the chemistry of the end-of-life polymer, to develop a robust recycling strategy that will provide customers with materials that fully meet all specifications.

MCAM has already partnered with Solvay in reclamation and recycling of other high-performance polymers, including KetaSpire® polyetheretherketone (PEEK).

“Giving back more than we take is at the heart of MCAM’s strategy and sustainability approach. We have adopted the concept of KAITEKI to help us achieve our sustainability objectives based on our core values of environmental, social and human well-being,” says Henning Bloech, Global Director Sustainable Solutions for Mitsubishi Chemical Advanced Materials. “We fully support our partner Solvay in this effort. We look forward to maximizing the potential of our synergies to help customers tackle the global challenge of plastic waste.”

Together with Solvay’s polymer chemistry expertise, MCAM’s mastery of mechanical recycling will help overcome the special challenges customers face to recycle and reuse such polymers in demanding applications in support of the circular economy.

Udel® and KetaSpire® are registered trademarks of Solvay.

SourceSolvay

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version